Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 25:15:1561692.
doi: 10.3389/fonc.2025.1561692. eCollection 2025.

Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial

Vinod K Ramani  1 , Ajaikumar Basavalinga Sadashivaiah  2 , Radheshyam Naik  3
Affiliations

Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial

Vinod K Ramani et al. Front Oncol. .

Erratum in

Abstract

Background: Triple negative breast cancer (TNBC) is more prevalent among the younger age group and is the most aggressive form. Women with TNBC phenotype have 19% lower 5-year overall survival and 18% lower disease-free survival than their non-TNBC counterparts (1). Hence, extensive research is essential for the development of treatment modalities with high efficacy. Metformin is a widely used anti-diabetic drug. The research work has potential implications for re-purposing metformin in the clinical management of TNBC.

Methods: The study design includes a phase 2 randomized clinical trial of TNBC, with metformin given for the intervention arm and placebo oral tablet for the non-intervention arm. A total of 418 breast cancer patients are randomized with a parallel assignment model (209 each for the intervention and the control arms). This is an open-label trial where the primary purpose is treatment and adheres to the SPIRIT reporting guidelines. The trial will be initiated during January 2025 and is expected to be completed by May 2027.

Discussion: The clinical benefit, pathological response rate, and radiological response will be measured after 4.5 to 6 months of initiating treatment. The study will assess the recurrence-free survival (at intervals of 6 months) and overall survival at 2 years from treatment initiation. Patients who respond to the intervention are expected to have >50% decrease in the size of the primary tumor without the appearance of new lesions. RECIST v1.1 criteria are used to determine the objective tumor response for target lesions.

Keywords: metformin; neoadjuvant; remission; survival analysis; triple negative breast neoplasm.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming burden of triple-negative breast cancer in India. Clin Breast cancer.(2017) 18(3):e393-9. doi: 10.1016/j.clbc.2017.07.013 - DOI - PubMed
    1. Nwagu GC, Bhattarai S, Swaha M, Ahmed S, Aneja R. Prevalence and mortality of triple-negative breast cancer in west africa: biologic and sociocultural factors. JCO Global Oncol. (2021) 7. doi: 10.1200/GO.21.00082 - DOI - PMC - PubMed
    1. Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manage Res. (2019) 11:3295–313. doi: 10.2147/CMAR.S200059 - DOI - PMC - PubMed
    1. Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. (2016) 7:40767–80. doi: 10.18632/oncotarget.v7i26 - DOI - PMC - PubMed
    1. Barakat HE, Hussein RRS, Elberry AA, Zaki MA, Ramadan ME. The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. Sci Rep. (2022), 12(1):7656. doi: 10.1038/s41598-022-11138-3 - DOI - PMC - PubMed

LinkOut - more resources